Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions accepted in part — page 11

Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.

Submissions

390 documents · page 11 of 13

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-THIRD-PARTY-/006Draft standard CEI-MS-15: Protocol for independent third-party…Professor Bartolomeu Nkosi-LindegaardNothing prevents a chromatogram being reprocessed until it passes
DRAFT-THIRD-PARTY-/008Draft standard CEI-MS-15: Protocol for independent third-party…Dr Brigitta Grünbaum-SowandeAcceptance criteria are expressed in terms specific to one instrument family
DRAFT-THIRD-PARTY-/012Draft standard CEI-MS-15: Protocol for independent third-party…Dr Kolawole Isaksen-BalogunPoint estimates are given without an interval
DRAFT-APPEARANCE-S/003Draft standard CEI-MS-09: Assessment of appearance, cake integrity…Dr Nikolai Yeovil-BakareA single method cannot support the conclusion the standard permits
DRAFT-APPEARANCE-S/005Draft standard CEI-MS-09: Assessment of appearance, cake integrity…Dr Fenella Steenkamp-FerreiraA field classified as critical is not one a reading turns on
DRAFT-APPEARANCE-S/007Draft standard CEI-MS-09: Assessment of appearance, cake integrity…Dr Liesbeth Nyquist-ObioraNothing addresses the container the material was held in
DRAFT-APPEARANCE-S/012Draft standard CEI-MS-09: Assessment of appearance, cake integrity…Dr Melisande Thorsby-NakamuraA system suitability criterion is unachievable on instrumentation in general use
DRAFT-POORLY-RETAI/003Draft standard CEI-MS-19: Purity determination for peptides not…Dr Vasilisa ImmelmannNothing prevents a chromatogram being reprocessed until it passes
DRAFT-POORLY-RETAI/010Draft standard CEI-MS-19: Purity determination for peptides not…Dr Ottoline Fitzgerald-NwosuThe preparation solvent is not specified and changes what is measured
DRAFT-POORLY-RETAI/011Draft standard CEI-MS-19: Purity determination for peptides not…Dr Anselm Thorsby-NakamuraResults are reported without an estimate of measurement uncertainty
DRAFT-POORLY-RETAI/012Draft standard CEI-MS-19: Purity determination for peptides not…Dr Liesbeth Nyquist-ObioraNothing addresses the container the material was held in
DRAFT-PHOTOSTABILI/001Draft standard CEI-MS-20: Photostability assessment of…Dr Fenella Steenkamp-FerreiraA field classified as critical is not one a reading turns on
DRAFT-DUAL-VS-SING/001Draft synthesis: Dual and triple incretin receptor agonists compared…Ms Rhiannon Okoye-VandergraafPatient-reported outcomes are collected by the trials and not reported by the review
DRAFT-DUAL-VS-SING/005Draft synthesis: Dual and triple incretin receptor agonists compared…Dr Quentin EnthovenStudies not published in English were excluded without assessment
DRAFT-DUAL-VS-SING/006Draft synthesis: Dual and triple incretin receptor agonists compared…Stellan Cholmondeley-AdeReferences should carry a persistent identifier for every cited source
DRAFT-INCRETIN-CAR/001Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…Dr Vasilisa ImmelmannRegulatory assessment documents were not searched
DRAFT-INCRETIN-CAR/003Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…Thaddeus Isaksen-BalogunPoint estimates are given without an interval
DRAFT-INCRETIN-CAR/004Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…Dr Georgiana MountstephenStudies not published in English were excluded without assessment
DRAFT-INCRETIN-CAR/006Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…Dr Wojciech Kaltenbach-MensahA surrogate outcome is used as the anchor without validation evidence
DRAFT-INCRETIN-CAR/012Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…Dr Yaa KettlewellStatistical heterogeneity is treated as though it measured clinical heterogeneity
DRAFT-GASTROINTEST/004Draft synthesis: Gastrointestinal adverse events with incretin…Ivo MountstephenReferences should carry a persistent identifier for every cited source
DRAFT-GASTROINTEST/006Draft synthesis: Gastrointestinal adverse events with incretin…Dr Vasilisa ImmelmannRegulatory assessment documents were not searched
DRAFT-GASTROINTEST/010Draft synthesis: Gastrointestinal adverse events with incretin…Eamon Sandringham-AduThe review protocol is described but its registration record is not linked
DRAFT-GASTROINTEST/012Draft synthesis: Gastrointestinal adverse events with incretin…Dr Emiliana OllerenshawStudies not published in English were excluded without assessment
DRAFT-ORAL-VS-INJE/001Draft synthesis: Oral compared with injectable presentations of…Dr Yaa KettlewellSubgroup findings are reported that were not registered in the protocol
DRAFT-ORAL-VS-INJE/004Draft synthesis: Oral compared with injectable presentations of…Dr Wojciech Kaltenbach-MensahA surrogate outcome is used as the anchor without validation evidence
DRAFT-ORAL-VS-INJE/005Draft synthesis: Oral compared with injectable presentations of…Dr Vasilisa Sandringham-AduStudies not published in English were excluded without assessment
DRAFT-ORAL-VS-INJE/011Draft synthesis: Oral compared with injectable presentations of…Thaddeus Isaksen-BalogunPoint estimates are given without an interval
DRAFT-ORAL-VS-INJE/012Draft synthesis: Oral compared with injectable presentations of…Dr Odalys Thorsby-NakamuraThe same concern is used to downgrade in two domains
DRAFT-RENAL-OUTCOM/001Draft synthesis: Kidney outcomes with incretin receptor agonists in…Thaddeus Isaksen-BalogunCrossover trials are pooled with parallel-group trials without adjustment

page 11 of 13

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.